Whales with a lot of money to spend have taken a noticeably bearish stance on Madrigal Pharmaceuticals.
Looking at options history for Madrigal Pharmaceuticals MDGL we detected 18 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $406,640 and 11, calls, for a total amount of $7,767,431.
Latest Startup Investment Opportunities:
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $300.0 for Madrigal Pharmaceuticals over the last 3 months.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Madrigal Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Madrigal Pharmaceuticals's significant trades, within a strike price range of $85.0 to $300.0, over the past month.
Madrigal Pharmaceuticals Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MDGL | CALL | TRADE | NEUTRAL | 04/19/24 | $200.00 | $6.9M | 1.2K | 2.5K |
| MDGL | CALL | SWEEP | BULLISH | 04/19/24 | $200.00 | $262.2K | 1.2K | 209 |
| MDGL | CALL | SWEEP | BULLISH | 04/19/24 | $200.00 | $176.4K | 1.2K | 15 |
| MDGL | PUT | SWEEP | BEARISH | 03/15/24 | $90.00 | $143.1K | 0 | 254 |
| MDGL | PUT | SWEEP | BEARISH | 03/15/24 | $145.00 | $82.5K | 100 | 70 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
In light of the recent options history for Madrigal Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Madrigal Pharmaceuticals's Current Market Status
- With a volume of 582,350, the price of MDGL is up 1.53% at $174.0.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 13 days.
Expert Opinions on Madrigal Pharmaceuticals
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $336.0.
- Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Madrigal Pharmaceuticals with a target price of $336.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Madrigal Pharmaceuticals with Benzinga Pro for real-time alerts.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
